Novo's molecule semaglutide (commonly known by the trade names Ozempic and Wegovy) is already marketed to treat cardiometabolic illnesses like type 2 diabetes and obesity, both of which are illnesses ...

Wegovy and Ozempic drove Novo Nordisk to record bumper sales since the launch. In fact, the success story has turned the ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Novo Nordisk's Wegovy sales exceed forecasts, boosting shares by 9%. U.S. demand remains high with expanded supply plans and ...

Novo Nordisk's third-quarter sales for Wegovy exceeded expectations, relieving investors concerned about demand slowdown.

Novo Nordisk reports strong sales of Wegovy, propelling shares up 9%. Despite supply constraints, volumes are expected to ...

With ocedurenone gone, the only CKD program still listed in Novo’s pipeline is semaglutide—the main ingredient behind ...

As demand for popular weight-loss drugs like Wegovy and Zepbound skyrockets, patients are taking dosage amounts into their ...

Dr Lotte Knudson, a scientist from Copenhagen, revolutionized research into drugs used by millions to lose weight. She has ...

“A balanced diet will help fuel your body for long-term success, keeping you on track even after you’re done with the ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...